Literature DB >> 21670231

Nonmuscle myosin light-chain kinase deficiency attenuates atherosclerosis in apolipoprotein E-deficient mice via reduced endothelial barrier dysfunction and monocyte migration.

Chongxiu Sun1, Mack H Wu, Sarah Y Yuan.   

Abstract

BACKGROUND: Endothelial dysfunction and monocyte migration are key events in the pathogenesis of atherosclerosis. Nonmuscle myosin light-chain kinase (nmMLCK), the predominant MLCK isoform in endothelial cells, has been shown to contribute to vascular inflammation by altering endothelial barrier function. However, its impact on atherogenesis remains unknown. METHODS AND
RESULTS: We investigated the role of nmMLCK in the development of atherosclerotic lesions in apolipoprotein E-deficient (apoE(-/-)) mice fed an atherogenic diet for 12 weeks. Histopathological examination demonstrated that nmMLCK deficiency (apoE(-/-)nmmlck(-/-)) reduced the size of aortic lesions by 53%, lipid contents by 44%, and macrophage deposition by 40%. Western blotting and reverse-transcription polymerase chain reaction revealed the expression of nmMLCK in aortic endothelial cells and peripheral blood monocytes. Measurements of transendothelial electric resistance indicated that nmMLCK deficiency attenuated endothelial barrier dysfunction caused by thrombin, oxidized low-density lipoprotein, and tumor necrosis factor α. In monocytes, nmMLCK deficiency reduced their migration in response to the chemokine monocyte chemoattractant protein-1. Further mechanistic studies showed that nmMLCK acted through both myosin light chain phosphorylation-coupled and -uncoupled pathways; the latter involved Rous sacracoma virus homolog genes-encoded tyrosine kinases (Src) signaling. Moreover, depletion of Src via gene silencing, site-specific mutagenesis, or pharmacological inhibition of Src greatly attenuated nmMLCK-dependent endothelial barrier dysfunction and monocyte migration.
CONCLUSIONS: Nonmuscle myosin light-chain kinase contributes to atherosclerosis by regulating endothelial barrier function and monocyte migration via mechanisms involving not only kinase-mediated MLC phosphorylation but also Src activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670231      PMCID: PMC3136817          DOI: 10.1161/CIRCULATIONAHA.110.988915

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

Review 1.  Leucocyte/endothelium interactions and microvessel permeability: coupled or uncoupled?

Authors:  Pingnian He
Journal:  Cardiovasc Res       Date:  2010-05-13       Impact factor: 10.787

2.  Signal transduction involved in MCP-1-mediated monocytic transendothelial migration.

Authors:  B Cambien; M Pomeranz; M A Millet; B Rossi; A Schmid-Alliana
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

3.  Myosin light-chain kinase regulates endothelial calcium entry and endothelium-dependent vasodilation.

Authors:  H Watanabe; Q K Tran; K Takeuchi; M Fukao; M Y Liu; M Kanno; T Hayashi; A Iguchi; M Seto; K Ohashi
Journal:  FASEB J       Date:  2000-12-08       Impact factor: 5.191

4.  Increased rate of apoptosis in intimal arterial smooth muscle cells through endogenous activation of TNF receptors.

Authors:  A Niemann-Jönsson; M P Ares; Z Q Yan; D X Bu; G N Fredrikson; L Brånén; I Pörn-Ares; A H Nilsson; J Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

5.  Differential regulation of alternatively spliced endothelial cell myosin light chain kinase isoforms by p60(Src).

Authors:  K G Birukov; C Csortos; L Marzilli; S Dudek; S F Ma; A R Bresnick; A D Verin; R J Cotter; J G Garcia
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

6.  Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.

Authors:  Galina K Sukhova; J Koudy Williams; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

7.  Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment.

Authors:  Mark S Wainwright; Janet Rossi; James Schavocky; Susan Crawford; David Steinhorn; Anastasia V Velentza; Magdalena Zasadzki; Vladimir Shirinsky; Yuzhi Jia; Jacques Haiech; Linda J Van Eldik; D Martin Watterson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

Review 8.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Myosin light chain phosphorylation in neutrophil-stimulated coronary microvascular leakage.

Authors:  Sarah Y Yuan; Mack H Wu; Elena E Ustinova; Mingzhang Guo; John H Tinsley; Primal De Lanerolle; Wenjuan Xu
Journal:  Circ Res       Date:  2002-06-14       Impact factor: 17.367

10.  Monocytes induce reversible focal changes in vascular endothelial cadherin complex during transendothelial migration under flow.

Authors:  J R Allport; W A Muller; F W Luscinskas
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

View more
  43 in total

Review 1.  Myosin light chain kinase signaling in endothelial barrier dysfunction.

Authors:  Robert R Rigor; Qiang Shen; Christopher D Pivetti; Mack H Wu; Sarah Y Yuan
Journal:  Med Res Rev       Date:  2012-08-09       Impact factor: 12.944

2.  MicroRNA-1907 enhances atherosclerosis-associated endothelial cell apoptosis by suppressing Bcl-2.

Authors:  Jin Zhao; Shu-Lin Ou; Wei-You Wang; Chang Yan; Lu-Xiang Chi
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

3.  Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice.

Authors:  Xingjuan Chen; Shaomin Qian; April Hoggatt; Hongying Tang; Timothy A Hacker; Alexander G Obukhov; Paul B Herring; Cheikh I Seye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-11-17       Impact factor: 8.311

4.  TIMAP repression by TGFβ and HDAC3-associated Smad signaling regulates macrophage M2 phenotypic phagocytosis.

Authors:  Jun Yang; Shasha Yin; Fangfang Bi; Lin Liu; Tian Qin; Hongwei Wang; Wangsen Cao
Journal:  J Mol Med (Berl)       Date:  2016-10-06       Impact factor: 4.599

5.  Inhibition of myosin light chain kinase reduces NADPH oxidase-mediated oxidative injury in rat brain following cerebral ischemia/reperfusion.

Authors:  Hong-Feng Zhang; Ting-Bo Li; Bin Liu; Zheng Lou; Jie-Jie Zhang; Jing-Jie Peng; Xiao-Jie Zhang; Qi-Lin Ma; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-29       Impact factor: 3.000

6.  Astragaloside IV alleviates atherosclerosis through targeting circ_0000231/miR-135a-5p/CLIC4 axis in AS cell model in vitro.

Authors:  Xiao Shao; Zhaozheng Liu; Shanshan Liu; Na Lin; Yue Deng
Journal:  Mol Cell Biochem       Date:  2021-01-13       Impact factor: 3.396

7.  Nonmuscle myosin light-chain kinase mediates microglial migration induced by HIV Tat: involvement of β1 integrins.

Authors:  Honghong Yao; Ming Duan; Lu Yang; Shilpa Buch
Journal:  FASEB J       Date:  2013-01-04       Impact factor: 5.191

8.  Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells.

Authors:  Richard S Beard; Ricci J Haines; Kevin Y Wu; Jason J Reynolds; Stephanie M Davis; John E Elliott; Nikolay L Malinin; Victor Chatterjee; Byeong J Cha; Mack H Wu; Sarah Y Yuan
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

9.  A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src family kinase activity.

Authors:  Chongxiu Sun; Mack H Wu; Eugene S Lee; Sarah Y Yuan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-16       Impact factor: 8.311

10.  MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in atherosclerosis.

Authors:  Zhaohua Geng; Fei Xu; Yiguan Zhang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.